Veterinary Active Pharmaceutical Ingredients Manufacturing Business Analysis Report 2025-2030
Veterinary Active Pharmaceutical Ingredients Manufacturing Market
Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Veterinary Active Pharmaceutical Ingredients Manufacturing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Veterinary Active Pharmaceutical Ingredients Manufacturing was estimated at US$8.7 Billion in 2024 and is projected to reach US$12.5 Billion by 2030, growing at a CAGR of 6.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
What Factors Are Supporting Growth in Veterinary API Manufacturing Globally?Growth in the veterinary active pharmaceutical ingredients manufacturing market is driven by several factors related to rising demand for animal protein, increased companion animal care, and stricter disease management protocols. Expansion of commercial livestock farming and aquaculture is driving volume demand for antiparasitics, antibiotics, and nutritional APIs. Growth in pet ownership and veterinary clinics in both developed and emerging regions is supporting small-batch production of APIs for dermatological, cardiovascular, and endocrine therapies.
Regulatory mandates for controlled antimicrobial use are prompting reformulation efforts and development of narrow-spectrum APIs. Investments in regional API production hubs, particularly in Asia and Latin America, are improving supply chain stability and cost efficiency. Strategic outsourcing and technological modernization in synthesis, purification, and process validation are further enhancing the capacity and compliance of veterinary API manufacturing facilities worldwide.
Why Is Veterinary API Manufacturing Central to Animal Health Supply Chains?Veterinary active pharmaceutical ingredients (APIs) are the core biologically active substances used to formulate medications for animals. These APIs form the basis of drugs used for disease prevention, treatment, and performance enhancement in livestock, companion animals, and aquatic species. Veterinary API manufacturing supports a wide spectrum of products, including antibiotics, anti-parasitics, anti-inflammatories, and vaccines. The manufacturing process involves synthesis, fermentation, purification, and formulation of APIs that meet regulatory quality standards for animal use.Manufacturing of veterinary APIs must adhere to specific pharma-copoeial guidelines and good manufacturing practices (GMP), with added emphasis on contamination control and species-specific efficacy. As animal health becomes closely tied to food safety, public health, and economic productivity, secure and consistent API supply is essential for the continuity of veterinary healthcare systems. This has heightened the focus on supply chain resilience, particularly for high-volume livestock drugs used in poultry, swine, and bovine segments.How Are Regulatory Shifts and Global Trade Influencing API Production?Veterinary API manufacturing is shaped by evolving regulatory frameworks focused on drug residue limits, antimicrobial stewardship, and export quality compliance. Many regions now require traceability and transparent documentation of the origin and composition of veterinary drugs. This has increased scrutiny on API manufacturers and driven demand for production facilities that comply with veterinary GMP standards, such as those issued by the FDA, EMA, and national veterinary authorities.International trade of veterinary APIs is also affected by harmonization initiatives, such as VICH guidelines and Codex Alimentarius standards. These influence residue monitoring programs and acceptable daily intake limits for veterinary drugs in animal-derived food products. Manufacturers must navigate differing approval pathways for veterinary APIs across regions, often requiring customized production and documentation for each export destination. These compliance requirements are prompting both large and mid-sized API producers to expand certifications, improve audit readiness, and invest in region-specific regulatory expertise.What Role Do Process Technologies and Outsourcing Models Play in Manufacturing Strategy?Advancements in synthesis, fermentation, and downstream processing technologies are enabling greater control over purity, yield, and production cost. Manufacturers are increasingly adopting continuous processing and modular production systems to improve throughput and reduce contamination risks. Microbial and enzymatic synthesis methods are being applied to veterinary hormone and vitamin APIs, while complex molecules such as antiparasitic agents require highly controlled chemical synthesis workflows.Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are playing a larger role in veterinary API supply chains. Many animal health companies outsource API production to dedicated third-party producers who specialize in veterinary-grade materials. This model supports scalability, cost optimization, and regulatory compliance while allowing drug developers to focus on formulation and distribution. As veterinary pharmaceutical pipelines diversify into biologics, CMOs with biologics capabilities are becoming integral partners in active ingredient development.
Report Features:
Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of players such as Alivira Animal Health Limited, AMGIS Lifescience Ltd, Ceva Sante Animale S.A., Chempro Pharma Private Limited, Divi`s Laboratories Limited and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Insights:
Market Growth: Understand the significant growth trajectory of the In House Service segment, which is expected to reach US$9.3 Billion by 030 with a CAGR of a 7.1%. The Contract Outsourcing Service segment is also set to grow at 4.0% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, estimated at $2.4 Billion in 2024, and China, forecasted to grow at an impressive 10.0% CAGR to reach $2.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Scope of Study:
Service (In House Service, Contract Outsourcing Service)
Synthesis Type (Chemical-based API Synthesis, Biological API Synthesis, HPAPI Synthesis)
Animal Type (Production Animals, Companion Animals)
Therapeutic Category (Antiparasitic Therapeutic, Anti-infectives Therapeutic, NSAIDs Therapeutic, Other Therapeutic Categories)
Key Attributes:
Report Attribute
Details
No. of Pages
458
Forecast Period
2024 - 2030
Estimated Market Value in 2024
8.7 Billion
Forecasted Market Value by 2030
12.5 Billion
Compound Annual Growth Rate
6.3%
Regions Covered
Global
Key Topics Covered:
MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Veterinary Active Pharmaceutical Ingredients Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
MARKET TRENDS & DRIVERS
Rising Global Demand for Livestock Health and Productivity Enhances Investment in Veterinary API Manufacturing Capacity
Expansion of Companion Animal Healthcare Markets Strengthens the Business Case for High-Purity Veterinary API Production
Growing Incidence of Zoonotic Diseases Spurs Innovation in Veterinary Antibiotics and Antiviral API Manufacturing
Stringent Regulatory Compliance in Animal Drug Approvals Drives Adoption of GMP-Certified Veterinary API Facilities
Surge in Global Meat and Dairy Consumption Fuels Demand for Anti-Infective and Growth-Promoting Veterinary APIs
Increasing R&D in Targeted Parasiticides and Antimicrobials Creates Opportunities for Specialized Veterinary API Manufacturers
Shift Toward Preventive Animal Health and Immunotherapy Supports Expansion of Veterinary API Pipelines
Rising Demand for Customized and Species-Specific Formulations Promotes Diversification of Veterinary API Product Lines
Growing Adoption of Biologics and Peptide-Based APIs in Veterinary Medicine Spurs Biotech-Oriented Manufacturing Investments
Globalization of Veterinary Drug Supply Chains Strengthens Outsourcing Trends in API Production
FOCUS ON SELECT PLAYERS | Some of the 32 Companies Featured in This Market Report
Alivira Animal Health Limited
AMGIS Lifescience Ltd
Ceva Sante Animale S.A.
Chempro Pharma Private Limited
Divi`s Laboratories Limited
Excel Industries Limited
FIS - Fabbrica Italiana Sintetici S.p.A.
Grupo Indukern S.L.
Huvepharma AD
Jiangsu Lingyun Pharmaceutical Co., Ltd.
Menadiona S.L.
Neuland Laboratories Limited
NGL Fine-Chem Ltd.
Norbrook Laboratories Limited
OFICHEM Group B.V.
Phibro Animal Health Corporation
Qilu Pharma Spain S.A.
Sequent Scientific Limited
SUANFARMA S.A.
Vetoquinol S.A.
Vetpharma Animal Health S.L.
Virbac S.A.
Zoetis Inc.
For more information about this report visit https://www.researchandmarkets.com/r/piqxjx
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Veterinary Active Pharmaceutical Ingredients Manufacturing Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
20 minutes ago
- Entrepreneur
James Dyson Created His 'Mad' Vacuum Idea While $1M in Debt
It took James Dyson five years of work and 5,127 failed prototypes to create the world's first bagless vacuum cleaner. In 1978, James Dyson had an idea for a bagless vacuum cleaner that maintained suction. He was frustrated with what was considered to be a top-of-the-line model, which he said frequently clogged and lost cleaning power as soon as it filled with dust. Dyson worked on his idea full-time, and after five years of work and 5,127 failed prototypes, he created the world's first bagless vacuum cleaner — the now-famous Dyson, which has since become a consumer electronics brand reaching sales of $9.6 billion in 2023. But those early years came at a cost: He was borrowing heavily from the bank to make ends meet and had accumulated over $1 million in debt. "Eventually, I owed over a million dollars, which for a penniless person in those days, going back 30 odd years, was a lot of money," Dyson, 78, told Entrepreneur in an interview. "I didn't have any money." Related: Emma Grede Dropped Out of School at 16. Now the Skims Boss Runs a $4 Billion Empire. But he also had "little to lose," he says, which is why he took a chance on his vacuum idea despite the financial pit. He lost his father at a young age and felt a keen sense of ownership and passion for what he was building and for his future. "I suppose I don't mind living on the edge," Dyson said. "I lost my father when I was nine years old. I had it built into me that my future was entirely down to me, and to do it on my own." "I wanted to do it," he added. James Dyson. Credit: Dyson Financial constraints made Dyson more creative because not having money taught him how to cope without it. For example, he couldn't hire salespeople, advertisers, or promoters, so he went out himself to sell the vacuum cleaner. "It took quite a long time," Dyson said. "Almost every businessperson I spoke to said that I was mad." Related: Nick Offerman's Side Hustle as an Actor Helps Fund the Business He Started 23 Years Ago — and Still Works at Every Day In 1993, Dyson set up his own shop and produced the first unit of the Dyson Dual Cyclone DC-01 vacuum cleaner at a price of $399. By 1998, Dyson had sold 1.4 million units of the vacuum globally, and by 2004, the DC-01 was cemented as a commercial success, outselling its nearest competitor in the U.K. by a ratio of five to one, per Industry Week. In recent years, Dyson's eponymous company has reached new heights. In 2023, with a broader product portfolio, including hair tools, lighting, fans, and headphones, Dyson's company achieved a record global revenue of £7.1 billion ($9.6 billion) and employed 6,500 workers. Revenue increased 9% from the previous year. Now, Dyson's net worth is reportedly around $15.3 billion, making him the third-wealthiest person in the U.K. He's received other honors, too, including a knighthood in 2006 for his services to business. Related: A Billionaire Founder Admits He Had 'Horrible Habits' — Then He Started a Morning Routine That 'Transformed' His Life Dyson has certainly paid off those early debts and says he celebrates the "little successes" just as much (or even more) than the big ones. He points to Dyson hand dryers as an example — the product isn't a "huge" business, like, say, the Dyson hair dryer, he says, but he still finds it "interesting." "You shouldn't do everything in life just to get big numbers, big successes," Dyson said. "Little successes are just as satisfying."
Washington Post
22 minutes ago
- Washington Post
Wrexham smashes its transfer record by signing Broadhead in a deal worth up to $13.5M
Wrexham's spending moved into a new stratosphere Thursday when the team owned by Hollywood celebrities signed winger Nathan Broadhead from Ipswich in a club-record deal that could reportedly reach 10 million pounds ($13.50 million). It took the Welsh club's outlay in the transfer market to more than 20 million pounds ($27 million) in this window as Wrexham reshapes its squad for life in the second-tier Championship following an unprecedented three straight promotions .
Bloomberg
22 minutes ago
- Bloomberg
Russia Plans to Extend Gasoline Export Ban Amid Drone Attacks
Russia plans to extend its ban on gasoline exports from fuel producers through September to ensure domestic supplies as Ukrainian drone attacks disrupt major refineries. Deputy Prime Minister Alexander Novak supported the plan to extend the restrictions, currently in place until the end of August, 'in order to maintain a stable situation on the domestic fuel market during the period of high seasonal demand and agricultural field work,' the government said in statement. The ban for non-producers can be extended through October.
